

AMERICAN COLLEGE OF SURGEONS Inspiring Quality: Highest Standards, Better Outcomes

100+years





Cancer Quality Improvement Program Newton-Wellesley Hospital

6141530

Newton, MA





Updated February 2018

Quality Measure Reports – Breast

- BCSRT: Breast radiation after breast conserving surgery (NQF 0219 – Accountability)
- **HT:** Adjuvant hormonal therapy for hormone receptor positive breast cancer (NQF 0220 Accountability)
- **BCS:** Breast conserving surgery rate (Surveillance)
- **nBx:** Image or palpation-guided needle biopsy (core or FNA) is performed for the diagnosis of breast cancer (Quality Improvement)


NQF = National Quality Forum Endorsed Measure







BREAST, 2015, BCSRT: Breast radiation after breast conserving surgery (NQF 0219 - Accountability)



24	My Program	My State (MA)	My Census Region (New England)		My CoC Program Type (CCCP)	All CoC Programs
Performance Rate	100 %	93. <mark>9</mark> %	<mark>94.5 %</mark>	<mark>94.5 %</mark>	<mark>91.9 %</mark>	92 %
Denominator	55	1892	4091	4091	24844	56406
95 % CI	(100.0,100.0)	(92.8,95.0)	(93.8,95.2)	(93.8,95.2)	(91.6,92.2)	(91.8,92.2)

Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer. (CP3R data as of 02/15/2018)




AMERICAN COLLEGE OF SURGEONS Inspiring Quality: Highest Standards, Better Outcomes





BREAST, 2015, HT: Adjuvant hormonal therapy for hormone receptor positive breast cancer (NQF 0220 - Accountability)



201	My Program	My State (MA)	My Census Region (New England)		My CoC Program Type (CCCP)	All CoC Programs
Performance Rate	100 %	95. <mark>6</mark> %	95.7 %	95. <mark>7</mark> %	92.6 %	92.7 %
Denominator	45	1822	4282	4282	34137	75406
95 % CI	(100.0,100.0)	(94.7,96.5)	(95.1,96.3)	(95.1,96.3)	(92.3,92.9)	(92.5,92.9)

Tamoxifen or third generation Aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB - III hormone receptor positive breast cancer. (CP3R data as of 02/15/2018)










BREAST, 2015, BCS: Breast conserving surgery rate (Surveillance)



	My Program	My State (MA)	My Census Region (New England)		My CoC Program Type (CCCP)	All CoC Programs
Performance Rate	77. <mark>3</mark> %	79.1 %	76.1 %	76.1 %	66.3 %	66.3 %
Denominator	128	3000	7052	7052	54907	120278
95 % CI	(70.0,84.6)	(77.6,80.6)	(75.1,77.1)	(75.1,77.1)	(65.9,66.7)	(66.0,66.6)

Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer. (CP3R data as of 02/15/2018)




AMERICAN COLLEGE OF SURGEONS Inspiring Quality: Highest Standards, Better Outcomes





BREAST, 2015, nBx: Image or palpation-guided needle biopsy (core or FNA) is performed for the diagnosis of breast cancer (Quality Improvement)



	My Program	My State (MA)	My Census Region (New England)	My ACS Division (New England)	My CoC Program Type (CCCP)	All CoC Programs
Performance Rate	85.5 %	92.1 %	92.7 %	92.7 %	92 %	92.1 %
Denominator	165	3421	7965	7965	60672	126429
95 % CI	(80.1,90.9)	(91.2,93.0)	(92.1,93.3)	(92.1,93.3)	(91.8,92.2)	(92.0,92.2)

Image or palpation-guided needle biopsy (core or FNA) is performed to establish diagnosis of breast cancer. (CP3R data as of 02/15/2018)




AMERICAN COLLEGE OF SURGEONS Inspiring Quality: Inspiring Standards, Better Outcomes





Stage Distribution - Breast Cancer Diagnosed in 2015, My Facility vs. All CoC





AMERICAN COLLEGE OF SURGEONS Inspiring Quality: Highest Standards, Better Outcomes





Cancer Program Total Case Volume, 2011 - 2015 My Facility

	2011	2012	2013	2014	2015
Breast	267	252	309	261	241
Colon	43	59	43	58	64
Lung, Bronchus - Non-Small Cell Carcinoma	66	<mark>48</mark>	51	<mark>53</mark>	59
Urinary Bladder	70	61	56	59	57
Corpus Uteri	30	27	30	26	32
NHL - Nodal	14	19	18	18	23
Rectum	20	14	15	23	22
Thyroid	5	7	<mark>1</mark> 8	29	19
Prostate	30	13	22	25	16
Melanoma of the Skin	4	8	8	5	14
All Other Sites	133	153	127	127	106
TOTAL	682	661	697	684	653

If Miscellaneous appears in your table, note that this is a SEER-defined group. The exact primary sites and histologies included in this group may be found in the CQIP documentation



AMERICAN COLLEGE OF SURGEONS Inspiring Quality: Highest Standards, Better Outcomes







AMERICAN COLLEGE OF SURGEONS Inspiring Quality: Highest Standards, Better Outcomes

100+years





CQIP

Cancer Quality Improvement Program

Commission on Cancer www.facs.org/quality-programs/cancer/coc 312-202-5085

CQIP

www.facs.org/quality-programs/cancer/ncdb/qualitytools/cqip